Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.
You may also be interested in...
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.